Albendazole

RTI International congratulates Lao PDR in eliminating LF — a disabling disease impacting the lives of millions of people around the world RESEARCH TRIANGLE PARK, N.C., Oct. 18, 2023 /PRNewswire/ -- RTI International, a nonprofit research institute and leading international development organization, joins the Lao People's Democratic Republic (Lao PDR), World Health Organization, and the U.S. Agency for International Development (USAID) in celebrating Lao PDR's achievement of eliminating lymphatic filariasis as a public health problem. Also known as elephantiasis, lymphatic filariasis is a neglected tropical disease (NTD) that can cause swollen extremities in a person and lead to severe disfigurement and disability, as well as social and economic discrimination against those affected. As of the latest data released by WHO last week, more than 793 million people required treatment for this disease across 44 countries in Asia, Africa, the Western Pacific, and parts of the Caribbean and South America. WHO officially confirmed this week that the people of Lao PDR are no longer at risk of contracting the disease. "RTI sends our sincerest congratulations to the government of Lao PDR and its people for solving this pressing public health problem," said Tim Gabel, president and CEO of RTI International. "It is particularly significant given that Lao PDR achieved the elimination of trachoma as public health problem in 2017, demonstrating the power of national commitment to ending neglected tropical diseases." RTI supported this milestone through its leadership of USAID's Act to End NTDs | East program, which has advanced the sustainable control and elimination of NTDs in 13 countries across Africa, Asia and Latin America. RTI worked with the government of Lao PDR to compile the data and information needed to establish proof that the country had eliminated lymphatic filariasis as a public health problem. Additionally, with USAID support, RTI assisted the government to develop a plan to monitor and track progress against the disease to ensure elimination is sustained in the future. "Lao PDR is the latest example of a country that worked hard to go the last mile to reach lymphatic filariasis elimination and free its people from this disabling disease," said  Lisa Rotondo, Director of USAID's Act to End NTDs | East program at RTI. "Global momentum towards eliminating lymphatic filariasis as a public health problem, led by countries themselves, is only growing. We are proud to be among the partners that supported the Lao PDR Ministry of Health to achieve this important milestone for its people." The elimination of lymphatic filariasis in Lao PDR was supported by many partners including USAID, RTI, FHI360, WHO, Mac Foundation, and the Asian Development Bank. In addition, albendazole treatments were donated by GlaxoSmithKline through the WHO donation program for NTD medicines. The Southeast Asian country now becomes the 19th country to have achieved validation of lymphatic filariasis elimination, marking another important public health milestone for the country and globally. Recently, Bangladesh also eliminated lymphatic filariasis with support from the Act to End NTDs | East program, led by RTI. Learn more about RTI's work to control and eliminate NTDs around the globe Media Contact: Kerry Branon 919 708-8205 [email protected] SOURCE RTI International

‍‍转自：江苏省公共资源中心   编辑：wangxinglai20042023年02月23日，江苏省公共资源中心发布了《关于公示药品阳光采购拟挂网产品的通知》，本次涉及165个产品，公示期为2023年2月23日至2月27日17:00。通知原文各相关药品生产企业：根据《江苏省医疗保障局关于深入推进药品阳光采购的实施意见》（苏医保发〔2021〕64号）、《关于公示药品阳光挂网产品的函》（苏价采中心药函〔2023〕37号）的要求，已按相关程序进行了审核与确认，现将药品阳光采购拟挂网产品予以公示（详见附件）。主要品种：银杏叶片（薄膜衣）、阿苯达唑片、环孢素软胶囊、碳酸氢钠注射液、利巴韦林滴鼻液、盐酸环丙沙星滴眼液、脑血康胶囊、碳酸钙咀嚼片、卡维地洛片、碳酸镧咀嚼片、复方颠茄氢氧化铝片、小儿清热止咳口服液、氯霉素滴眼液、小儿复方氨酚烷胺片、氨酚伪麻那敏口服溶液、葡萄糖注射液、丙酸交沙霉素颗粒、复方丹参片、富马酸酮替芬片、复方丹参片、苯扎溴铵溶液、小柴胡颗粒等；公示期为2023年2月23日至2月27日17:00。如有异议，企业须在公示期内通过江苏省公共资源交易平台（药品分类采购-其他-阳光挂网采购申诉（202302-4））进行申诉，并提交相关证明材料。‍‍